CDXC - צמיחת רווחי EPS רבעונית ChromaDex Corporation

The quarterly EPS growth rate demonstrates the impact of ChromaDex Corporation (CDXC) R&D developments in cellular aging and Niagen, with the current level sitting around 5763.70. Leadership in the rejuvenation segment is based on the proven efficacy of its products, while ownership of exclusive patents for the nicotinamide riboside molecule creates a robust defensive barrier against competition.
פילוחים אנליטיים של חברת ChromaDex Corporation

To build a high-quality portfolio, I track net income per share dynamics, utilizing a calculation model that captures daily changes in quarterly EPS growth to identify early signs of factor alpha. Given that ChromaDex Corporation (CDXC) is fully focused on the US domestic market without external risks, the upward trend of the quarterly EPS growth index confirms the business's internal efficiency and the asset's fundamental stability.